[Comparative study of the effect of the thymus preparations thymoptin and thymalin on fibrin-monomer polymerization].
Pastorova. V E VE; Liapina. L A LA; Ashmarin. I P IP; Kudriashov. B A BA; Zazhireĭ. V D VD
Key Findings
- Thymoptin can lyse non‑stabilized fibrin and boost non‑enzymatic fibrinolytic activity in rats
- Thymalin shows no fibrinolytic activity in vitro
- High concentrations of thymalin enhance fibrin‑monomer polymerization, promoting clot formation
Practical Outcomes
- Thymalin is unlikely to provide clot‑breaking benefits and may increase clotting risk if taken in large amounts. Biohackers focused on cardiovascular or longevity goals should be cautious and not rely on thymalin for blood‑thinning effects. No specific dosing guidance emerges from this work.
Summary
The study found that thymalin does not break down blood clots and, at high concentrations, actually helps clots form, while a related peptide, thymoptin, can dissolve clots in lab tests and in rats.
Abstract
Thymoptin was shown to possess the ability of lysis of the nonstabilized fibrin in vitro and of increasing the nonenzymatic fibrinolytic activity of blood plasma after eight daily intramuscular injections to rats in doses of 1 and 100 micrograms/kg body weight and during incubation with purified fibrin monomer to produce its depolymerization. Thymalin possessed no nonenzymatic fibrinolytic activity in vitro and in contrast to thymoptin at a relatively high concentration (1000 and 100 micrograms/ml) enhanced fibrin-monomer polymerization.
Study Information
pubmed
1989